Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 49,000 shares, an increase of 67.2% from the July 15th total of 29,300 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 118,600 shares, the days-to-cover ratio is presently 0.4 days.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Cadrenal Therapeutics in a research report on Thursday, June 6th.
View Our Latest Report on Cadrenal Therapeutics
Cadrenal Therapeutics Stock Up 12.6 %
About Cadrenal Therapeutics
Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Read More
- Five stocks we like better than Cadrenal Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- How to Invest in Mutual Funds
- Most active stocks: Dollar volume vs share volume
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- Insider Buying Explained: What Investors Need to Know
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.